Subcutaneous bortezomib: in multiple myeloma.

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Bortezomib is a proteasome inhibitor used in multiple myeloma treatment.
• A subcutaneous formulation of bortezomib has received regulatory approval in the EU and US.
• This formulation offers a new administration route for patients with multiple myeloma.

Purpose of the Study:

• To review pharmacological, efficacy, and tolerability data of subcutaneous bortezomib.
• To compare subcutaneous bortezomib with the intravenous formulation in treating relapsed multiple myeloma.
• To evaluate the safety profile, particularly peripheral neuropathy incidence.

Main Methods:

• A randomized, nonblind, phase III study was conducted.
• Adult patients with relapsed multiple myeloma were included.
• Outcomes measured included overall response rate, time to response, progression-free survival, and overall survival.

Main Results:

• Subcutaneous bortezomib demonstrated noninferiority to intravenous bortezomib based on overall response rate.
• No significant differences were observed in time to response, progression-free survival, or overall survival.
• A significant reduction in the incidence of peripheral neuropathy (all grades) was observed with the subcutaneous formulation.

Conclusions:

• Subcutaneous bortezomib is a viable and effective treatment option for multiple myeloma.
• The subcutaneous route offers a favorable safety profile, especially regarding peripheral neuropathy.
• This formulation provides a valuable alternative for patients, particularly those with pre-existing or high-risk neuropathy.